Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice
Probiotics have been used to treat human gastrointestinal inflammations including inflammatory bowel disease (IBD). However, the exact mechanisms by which probiotics act to protect against intestinal inflammation have yet to be fully elucidated. The aim of this study was to evaluate anti-inflammator...
Gespeichert in:
| Veröffentlicht in: | International immunopharmacology 2009-11, Vol.9 (12), p.1444-1451 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1451 |
|---|---|
| container_issue | 12 |
| container_start_page | 1444 |
| container_title | International immunopharmacology |
| container_volume | 9 |
| creator | Nishitani, Yosuke Tanoue, Takeshi Yamada, Katsushige Ishida, Tsukasa Yoshida, Masaru Azuma, Takeshi Mizuno, Masashi |
| description | Probiotics have been used to treat human gastrointestinal inflammations including inflammatory bowel disease (IBD). However, the exact mechanisms by which probiotics act to protect against intestinal inflammation have yet to be fully elucidated. The aim of this study was to evaluate anti-inflammatory effects of
Lactococcus lactis subsp.
cremoris FC using
in vivo and
in vitro inflammation models. Colitis was induced in C57BL/6 mice by administration of 3% dextran sulfate sodium to drinking water. In the cellular level assessment, a gut inflammation model with the co-culture system consisting Caco-2 cells and RAW264.7 cells stimulated by LPS was used. Administration of
L. lactis subsp.
cremoris FC significantly ameliorated shortening of colon length and histological score of the colon in DSS-induce colitis mice. In addition, the treatment of
L. lactis subsp.
cremoris FC improved the aberrant mRNA expression in inflamed tissue near to control level through notable suppression of TNF-α (
P
<
0.05), IFN-γ (
P
<
0.05), IL-6, iNOS, and MIP-2 mRNA expression. In addition, in a gut inflammation model, treatment with
L. lactis subsp.
cremoris FC resulted in significant down-regulation of IL-8 mRNA expression in Caco-2 cells and inhibition of NF-κB nuclear translocation in RAW264.7 cells. Our findings indicate that administration of
L. lactis subsp.
cremoris FC improves negative effects of DSS-induced colitis in mice through the inhibition of inflammatory cell infiltration. |
| doi_str_mv | 10.1016/j.intimp.2009.08.018 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_733529952</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576909002586</els_id><sourcerecordid>733529952</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-30e06ac0ad7ac8cf861957a87aa5877819f5dff4474ddd02a43ed4a87011db283</originalsourceid><addsrcrecordid>eNp9kU-LFDEQxRtR3HX1G4jkop66rXQnnfRFWAZXhQEveg6Z_IEMSadNuhfn21vDDHrbUyqpXz0q7zXNWwodBTp-OnZhXkNauh5g6kB2QOWz5pZKIVsqgD_Hmo-i5WKcbppXtR4B8J3Rl80NncQwjJO4bea9Nms22Zitkoh1qKRuh7p0xBSXcsH7w47oGN1j0KvD7ikta06VZE9MjuE8EWa7GWfJ4USs-7MWPaNI9MiTmm3YEhIkBeNeNy-8jtW9uZ53za-HLz9339r9j6_fd_f71jAp13YAB6M2oK3QRhovRzpxoaXQmkshJJ08t94zJpi1FnrNBmcZ9oFSe-jlcNd8vOguJf_eXF1VCtW4GPXs8lYVfp_308R7JD88Sfa0pxyAIcguoCm51uK8WkpIupwUBXVORB3VJRF1TkSBVJgIjr276m-H5Oz_oWsECLy_AroaHT2aZ0L9x_U9MMYFIPf5wjn07TG4oqoJbkbbQ3FmVTaHpzf5C56arQk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>21215004</pqid></control><display><type>article</type><title>Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice</title><source>Elsevier ScienceDirect Journals Complete - AutoHoldings</source><source>MEDLINE</source><creator>Nishitani, Yosuke ; Tanoue, Takeshi ; Yamada, Katsushige ; Ishida, Tsukasa ; Yoshida, Masaru ; Azuma, Takeshi ; Mizuno, Masashi</creator><creatorcontrib>Nishitani, Yosuke ; Tanoue, Takeshi ; Yamada, Katsushige ; Ishida, Tsukasa ; Yoshida, Masaru ; Azuma, Takeshi ; Mizuno, Masashi</creatorcontrib><description>Probiotics have been used to treat human gastrointestinal inflammations including inflammatory bowel disease (IBD). However, the exact mechanisms by which probiotics act to protect against intestinal inflammation have yet to be fully elucidated. The aim of this study was to evaluate anti-inflammatory effects of
Lactococcus lactis subsp.
cremoris FC using
in vivo and
in vitro inflammation models. Colitis was induced in C57BL/6 mice by administration of 3% dextran sulfate sodium to drinking water. In the cellular level assessment, a gut inflammation model with the co-culture system consisting Caco-2 cells and RAW264.7 cells stimulated by LPS was used. Administration of
L. lactis subsp.
cremoris FC significantly ameliorated shortening of colon length and histological score of the colon in DSS-induce colitis mice. In addition, the treatment of
L. lactis subsp.
cremoris FC improved the aberrant mRNA expression in inflamed tissue near to control level through notable suppression of TNF-α (
P
<
0.05), IFN-γ (
P
<
0.05), IL-6, iNOS, and MIP-2 mRNA expression. In addition, in a gut inflammation model, treatment with
L. lactis subsp.
cremoris FC resulted in significant down-regulation of IL-8 mRNA expression in Caco-2 cells and inhibition of NF-κB nuclear translocation in RAW264.7 cells. Our findings indicate that administration of
L. lactis subsp.
cremoris FC improves negative effects of DSS-induced colitis in mice through the inhibition of inflammatory cell infiltration.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2009.08.018</identifier><identifier>PMID: 19733697</identifier><language>eng</language><publisher>Kidlington: Elsevier B.V</publisher><subject>Animal models ; Animals ; Anti-inflammatory ; Biological and medical sciences ; Caco-2 Cells ; Colitis ; Colitis - chemically induced ; Colitis - immunology ; Colitis - microbiology ; Colitis - physiopathology ; Colitis - therapy ; Colon ; Colon - immunology ; Colon - metabolism ; Colon - microbiology ; Colon - pathology ; Cytokines - genetics ; Cytokines - immunology ; Cytokines - metabolism ; Dextran sulfate ; Dextran Sulfate - administration & dosage ; Digestive tract ; Drinking water ; DSS-induced colitis ; Enterocytes - immunology ; Enterocytes - metabolism ; Enterocytes - microbiology ; Enterocytes - pathology ; Female ; g-Interferon ; Gene expression ; Gene Expression Regulation ; Gut inflammation in vitro model ; Humans ; Immunomodulation ; Inflammation ; Inflammatory bowel diseases ; Inflammatory Bowel Diseases - immunology ; Inflammatory Bowel Diseases - microbiology ; Inflammatory Bowel Diseases - therapy ; Interleukin 6 ; Interleukin 8 ; Intestine ; Lactococcus lactis ; Lactococcus lactis - immunology ; Lactococcus lactis subsp. cremoris FC ; Lipopolysaccharides ; Lipopolysaccharides - metabolism ; Macrophages - immunology ; Macrophages - metabolism ; Macrophages - microbiology ; Macrophages - pathology ; Medical sciences ; Mice ; Mice, Inbred C57BL ; NF-B protein ; NF-kappa B - immunology ; NF-kappa B - metabolism ; Nitric Oxide Synthase Type II - genetics ; Nitric Oxide Synthase Type II - immunology ; Nitric Oxide Synthase Type II - metabolism ; Nitric-oxide synthase ; Nuclear transport ; Pharmacology. Drug treatments ; probiotics ; Probiotics - administration & dosage ; Probiotics - pharmacology ; Sodium ; Tumor necrosis factor-a</subject><ispartof>International immunopharmacology, 2009-11, Vol.9 (12), p.1444-1451</ispartof><rights>2009 Elsevier B.V.</rights><rights>2009 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-30e06ac0ad7ac8cf861957a87aa5877819f5dff4474ddd02a43ed4a87011db283</citedby><cites>FETCH-LOGICAL-c488t-30e06ac0ad7ac8cf861957a87aa5877819f5dff4474ddd02a43ed4a87011db283</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2009.08.018$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,778,782,3539,27911,27912,45982</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22044570$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19733697$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nishitani, Yosuke</creatorcontrib><creatorcontrib>Tanoue, Takeshi</creatorcontrib><creatorcontrib>Yamada, Katsushige</creatorcontrib><creatorcontrib>Ishida, Tsukasa</creatorcontrib><creatorcontrib>Yoshida, Masaru</creatorcontrib><creatorcontrib>Azuma, Takeshi</creatorcontrib><creatorcontrib>Mizuno, Masashi</creatorcontrib><title>Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>Probiotics have been used to treat human gastrointestinal inflammations including inflammatory bowel disease (IBD). However, the exact mechanisms by which probiotics act to protect against intestinal inflammation have yet to be fully elucidated. The aim of this study was to evaluate anti-inflammatory effects of
Lactococcus lactis subsp.
cremoris FC using
in vivo and
in vitro inflammation models. Colitis was induced in C57BL/6 mice by administration of 3% dextran sulfate sodium to drinking water. In the cellular level assessment, a gut inflammation model with the co-culture system consisting Caco-2 cells and RAW264.7 cells stimulated by LPS was used. Administration of
L. lactis subsp.
cremoris FC significantly ameliorated shortening of colon length and histological score of the colon in DSS-induce colitis mice. In addition, the treatment of
L. lactis subsp.
cremoris FC improved the aberrant mRNA expression in inflamed tissue near to control level through notable suppression of TNF-α (
P
<
0.05), IFN-γ (
P
<
0.05), IL-6, iNOS, and MIP-2 mRNA expression. In addition, in a gut inflammation model, treatment with
L. lactis subsp.
cremoris FC resulted in significant down-regulation of IL-8 mRNA expression in Caco-2 cells and inhibition of NF-κB nuclear translocation in RAW264.7 cells. Our findings indicate that administration of
L. lactis subsp.
cremoris FC improves negative effects of DSS-induced colitis in mice through the inhibition of inflammatory cell infiltration.</description><subject>Animal models</subject><subject>Animals</subject><subject>Anti-inflammatory</subject><subject>Biological and medical sciences</subject><subject>Caco-2 Cells</subject><subject>Colitis</subject><subject>Colitis - chemically induced</subject><subject>Colitis - immunology</subject><subject>Colitis - microbiology</subject><subject>Colitis - physiopathology</subject><subject>Colitis - therapy</subject><subject>Colon</subject><subject>Colon - immunology</subject><subject>Colon - metabolism</subject><subject>Colon - microbiology</subject><subject>Colon - pathology</subject><subject>Cytokines - genetics</subject><subject>Cytokines - immunology</subject><subject>Cytokines - metabolism</subject><subject>Dextran sulfate</subject><subject>Dextran Sulfate - administration & dosage</subject><subject>Digestive tract</subject><subject>Drinking water</subject><subject>DSS-induced colitis</subject><subject>Enterocytes - immunology</subject><subject>Enterocytes - metabolism</subject><subject>Enterocytes - microbiology</subject><subject>Enterocytes - pathology</subject><subject>Female</subject><subject>g-Interferon</subject><subject>Gene expression</subject><subject>Gene Expression Regulation</subject><subject>Gut inflammation in vitro model</subject><subject>Humans</subject><subject>Immunomodulation</subject><subject>Inflammation</subject><subject>Inflammatory bowel diseases</subject><subject>Inflammatory Bowel Diseases - immunology</subject><subject>Inflammatory Bowel Diseases - microbiology</subject><subject>Inflammatory Bowel Diseases - therapy</subject><subject>Interleukin 6</subject><subject>Interleukin 8</subject><subject>Intestine</subject><subject>Lactococcus lactis</subject><subject>Lactococcus lactis - immunology</subject><subject>Lactococcus lactis subsp. cremoris FC</subject><subject>Lipopolysaccharides</subject><subject>Lipopolysaccharides - metabolism</subject><subject>Macrophages - immunology</subject><subject>Macrophages - metabolism</subject><subject>Macrophages - microbiology</subject><subject>Macrophages - pathology</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred C57BL</subject><subject>NF-B protein</subject><subject>NF-kappa B - immunology</subject><subject>NF-kappa B - metabolism</subject><subject>Nitric Oxide Synthase Type II - genetics</subject><subject>Nitric Oxide Synthase Type II - immunology</subject><subject>Nitric Oxide Synthase Type II - metabolism</subject><subject>Nitric-oxide synthase</subject><subject>Nuclear transport</subject><subject>Pharmacology. Drug treatments</subject><subject>probiotics</subject><subject>Probiotics - administration & dosage</subject><subject>Probiotics - pharmacology</subject><subject>Sodium</subject><subject>Tumor necrosis factor-a</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kU-LFDEQxRtR3HX1G4jkop66rXQnnfRFWAZXhQEveg6Z_IEMSadNuhfn21vDDHrbUyqpXz0q7zXNWwodBTp-OnZhXkNauh5g6kB2QOWz5pZKIVsqgD_Hmo-i5WKcbppXtR4B8J3Rl80NncQwjJO4bea9Nms22Zitkoh1qKRuh7p0xBSXcsH7w47oGN1j0KvD7ikta06VZE9MjuE8EWa7GWfJ4USs-7MWPaNI9MiTmm3YEhIkBeNeNy-8jtW9uZ53za-HLz9339r9j6_fd_f71jAp13YAB6M2oK3QRhovRzpxoaXQmkshJJ08t94zJpi1FnrNBmcZ9oFSe-jlcNd8vOguJf_eXF1VCtW4GPXs8lYVfp_308R7JD88Sfa0pxyAIcguoCm51uK8WkpIupwUBXVORB3VJRF1TkSBVJgIjr276m-H5Oz_oWsECLy_AroaHT2aZ0L9x_U9MMYFIPf5wjn07TG4oqoJbkbbQ3FmVTaHpzf5C56arQk</recordid><startdate>20091101</startdate><enddate>20091101</enddate><creator>Nishitani, Yosuke</creator><creator>Tanoue, Takeshi</creator><creator>Yamada, Katsushige</creator><creator>Ishida, Tsukasa</creator><creator>Yoshida, Masaru</creator><creator>Azuma, Takeshi</creator><creator>Mizuno, Masashi</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T5</scope><scope>C1K</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20091101</creationdate><title>Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice</title><author>Nishitani, Yosuke ; Tanoue, Takeshi ; Yamada, Katsushige ; Ishida, Tsukasa ; Yoshida, Masaru ; Azuma, Takeshi ; Mizuno, Masashi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-30e06ac0ad7ac8cf861957a87aa5877819f5dff4474ddd02a43ed4a87011db283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Animal models</topic><topic>Animals</topic><topic>Anti-inflammatory</topic><topic>Biological and medical sciences</topic><topic>Caco-2 Cells</topic><topic>Colitis</topic><topic>Colitis - chemically induced</topic><topic>Colitis - immunology</topic><topic>Colitis - microbiology</topic><topic>Colitis - physiopathology</topic><topic>Colitis - therapy</topic><topic>Colon</topic><topic>Colon - immunology</topic><topic>Colon - metabolism</topic><topic>Colon - microbiology</topic><topic>Colon - pathology</topic><topic>Cytokines - genetics</topic><topic>Cytokines - immunology</topic><topic>Cytokines - metabolism</topic><topic>Dextran sulfate</topic><topic>Dextran Sulfate - administration & dosage</topic><topic>Digestive tract</topic><topic>Drinking water</topic><topic>DSS-induced colitis</topic><topic>Enterocytes - immunology</topic><topic>Enterocytes - metabolism</topic><topic>Enterocytes - microbiology</topic><topic>Enterocytes - pathology</topic><topic>Female</topic><topic>g-Interferon</topic><topic>Gene expression</topic><topic>Gene Expression Regulation</topic><topic>Gut inflammation in vitro model</topic><topic>Humans</topic><topic>Immunomodulation</topic><topic>Inflammation</topic><topic>Inflammatory bowel diseases</topic><topic>Inflammatory Bowel Diseases - immunology</topic><topic>Inflammatory Bowel Diseases - microbiology</topic><topic>Inflammatory Bowel Diseases - therapy</topic><topic>Interleukin 6</topic><topic>Interleukin 8</topic><topic>Intestine</topic><topic>Lactococcus lactis</topic><topic>Lactococcus lactis - immunology</topic><topic>Lactococcus lactis subsp. cremoris FC</topic><topic>Lipopolysaccharides</topic><topic>Lipopolysaccharides - metabolism</topic><topic>Macrophages - immunology</topic><topic>Macrophages - metabolism</topic><topic>Macrophages - microbiology</topic><topic>Macrophages - pathology</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred C57BL</topic><topic>NF-B protein</topic><topic>NF-kappa B - immunology</topic><topic>NF-kappa B - metabolism</topic><topic>Nitric Oxide Synthase Type II - genetics</topic><topic>Nitric Oxide Synthase Type II - immunology</topic><topic>Nitric Oxide Synthase Type II - metabolism</topic><topic>Nitric-oxide synthase</topic><topic>Nuclear transport</topic><topic>Pharmacology. Drug treatments</topic><topic>probiotics</topic><topic>Probiotics - administration & dosage</topic><topic>Probiotics - pharmacology</topic><topic>Sodium</topic><topic>Tumor necrosis factor-a</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nishitani, Yosuke</creatorcontrib><creatorcontrib>Tanoue, Takeshi</creatorcontrib><creatorcontrib>Yamada, Katsushige</creatorcontrib><creatorcontrib>Ishida, Tsukasa</creatorcontrib><creatorcontrib>Yoshida, Masaru</creatorcontrib><creatorcontrib>Azuma, Takeshi</creatorcontrib><creatorcontrib>Mizuno, Masashi</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nishitani, Yosuke</au><au>Tanoue, Takeshi</au><au>Yamada, Katsushige</au><au>Ishida, Tsukasa</au><au>Yoshida, Masaru</au><au>Azuma, Takeshi</au><au>Mizuno, Masashi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2009-11-01</date><risdate>2009</risdate><volume>9</volume><issue>12</issue><spage>1444</spage><epage>1451</epage><pages>1444-1451</pages><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>Probiotics have been used to treat human gastrointestinal inflammations including inflammatory bowel disease (IBD). However, the exact mechanisms by which probiotics act to protect against intestinal inflammation have yet to be fully elucidated. The aim of this study was to evaluate anti-inflammatory effects of
Lactococcus lactis subsp.
cremoris FC using
in vivo and
in vitro inflammation models. Colitis was induced in C57BL/6 mice by administration of 3% dextran sulfate sodium to drinking water. In the cellular level assessment, a gut inflammation model with the co-culture system consisting Caco-2 cells and RAW264.7 cells stimulated by LPS was used. Administration of
L. lactis subsp.
cremoris FC significantly ameliorated shortening of colon length and histological score of the colon in DSS-induce colitis mice. In addition, the treatment of
L. lactis subsp.
cremoris FC improved the aberrant mRNA expression in inflamed tissue near to control level through notable suppression of TNF-α (
P
<
0.05), IFN-γ (
P
<
0.05), IL-6, iNOS, and MIP-2 mRNA expression. In addition, in a gut inflammation model, treatment with
L. lactis subsp.
cremoris FC resulted in significant down-regulation of IL-8 mRNA expression in Caco-2 cells and inhibition of NF-κB nuclear translocation in RAW264.7 cells. Our findings indicate that administration of
L. lactis subsp.
cremoris FC improves negative effects of DSS-induced colitis in mice through the inhibition of inflammatory cell infiltration.</abstract><cop>Kidlington</cop><pub>Elsevier B.V</pub><pmid>19733697</pmid><doi>10.1016/j.intimp.2009.08.018</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1567-5769 |
| ispartof | International immunopharmacology, 2009-11, Vol.9 (12), p.1444-1451 |
| issn | 1567-5769 1878-1705 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_733529952 |
| source | Elsevier ScienceDirect Journals Complete - AutoHoldings; MEDLINE |
| subjects | Animal models Animals Anti-inflammatory Biological and medical sciences Caco-2 Cells Colitis Colitis - chemically induced Colitis - immunology Colitis - microbiology Colitis - physiopathology Colitis - therapy Colon Colon - immunology Colon - metabolism Colon - microbiology Colon - pathology Cytokines - genetics Cytokines - immunology Cytokines - metabolism Dextran sulfate Dextran Sulfate - administration & dosage Digestive tract Drinking water DSS-induced colitis Enterocytes - immunology Enterocytes - metabolism Enterocytes - microbiology Enterocytes - pathology Female g-Interferon Gene expression Gene Expression Regulation Gut inflammation in vitro model Humans Immunomodulation Inflammation Inflammatory bowel diseases Inflammatory Bowel Diseases - immunology Inflammatory Bowel Diseases - microbiology Inflammatory Bowel Diseases - therapy Interleukin 6 Interleukin 8 Intestine Lactococcus lactis Lactococcus lactis - immunology Lactococcus lactis subsp. cremoris FC Lipopolysaccharides Lipopolysaccharides - metabolism Macrophages - immunology Macrophages - metabolism Macrophages - microbiology Macrophages - pathology Medical sciences Mice Mice, Inbred C57BL NF-B protein NF-kappa B - immunology NF-kappa B - metabolism Nitric Oxide Synthase Type II - genetics Nitric Oxide Synthase Type II - immunology Nitric Oxide Synthase Type II - metabolism Nitric-oxide synthase Nuclear transport Pharmacology. Drug treatments probiotics Probiotics - administration & dosage Probiotics - pharmacology Sodium Tumor necrosis factor-a |
| title | Lactococcus lactis subsp. cremoris FC alleviates symptoms of colitis induced by dextran sulfate sodium in mice |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T11%3A21%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lactococcus%20lactis%20subsp.%20cremoris%20FC%20alleviates%20symptoms%20of%20colitis%20induced%20by%20dextran%20sulfate%20sodium%20in%20mice&rft.jtitle=International%20immunopharmacology&rft.au=Nishitani,%20Yosuke&rft.date=2009-11-01&rft.volume=9&rft.issue=12&rft.spage=1444&rft.epage=1451&rft.pages=1444-1451&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2009.08.018&rft_dat=%3Cproquest_cross%3E733529952%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=21215004&rft_id=info:pmid/19733697&rft_els_id=S1567576909002586&rfr_iscdi=true |